MRK Quote, Financials, Valuation and Earnings

Biogen, Inc. has a net margin of 33.68% compared to Merck & Co., Inc.'s net margin of 19%. Merck & Co., Inc.'s return on equity of 39.63% beat Biogen, Inc.'s return on equity of 9.36%.

Merck & Co., Inc. has a consensus price target of $105.35, signalling upside risk potential of 3.01%. On the other hand Biogen, Inc. has an analysts' consensus of $178.76 which suggests that it could fall by -1.77%. Given that Merck & Co., Inc. has higher upside potential than Biogen, Inc., analysts believe Merck & Co., Inc. is more attractive than Biogen, Inc..

Merck & Co., Inc. has a beta of 0.294, which suggesting that the stock is 70.604% less volatile than S&P 500. In comparison Biogen, Inc. has a beta of 0.128, suggesting its less volatile than the S&P 500 by 87.226%.

Merck & Co., Inc. has a quarterly dividend of $0.81 per share corresponding to a yield of 3.17%. Biogen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merck & Co., Inc. pays 46.32% of its earnings as a dividend. Biogen, Inc. pays out -- of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Merck & Co., Inc. quarterly revenues are $17.2B, which are larger than Biogen, Inc. quarterly revenues of $2.5B. Merck & Co., Inc.'s net income of $5.8B is higher than Biogen, Inc.'s net income of $466.5M. Notably, Merck & Co., Inc.'s price-to-earnings ratio is 13.53x while Biogen, Inc.'s PE ratio is 16.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck & Co., Inc. is 4.03x versus 2.75x for Biogen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Cidara Therapeutics, Inc. has a net margin of 33.68% compared to Merck & Co., Inc.'s net margin of -30201.66%. Merck & Co., Inc.'s return on equity of 39.63% beat Cidara Therapeutics, Inc.'s return on equity of -68.74%.

Merck & Co., Inc. has a consensus price target of $105.35, signalling upside risk potential of 3.01%. On the other hand Cidara Therapeutics, Inc. has an analysts' consensus of $221.50 which suggests that it could grow by 0.45%. Given that Merck & Co., Inc. has higher upside potential than Cidara Therapeutics, Inc., analysts believe Merck & Co., Inc. is more attractive than Cidara Therapeutics, Inc..

Merck & Co., Inc. has a beta of 0.294, which suggesting that the stock is 70.604% less volatile than S&P 500. In comparison Cidara Therapeutics, Inc. has a beta of 1.461, suggesting its more volatile than the S&P 500 by 46.073%.

Merck & Co., Inc. has a quarterly dividend of $0.81 per share corresponding to a yield of 3.17%. Cidara Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merck & Co., Inc. pays 46.32% of its earnings as a dividend. Cidara Therapeutics, Inc. pays out -- of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Merck & Co., Inc. quarterly revenues are $17.2B, which are larger than Cidara Therapeutics, Inc. quarterly revenues of --. Merck & Co., Inc.'s net income of $5.8B is higher than Cidara Therapeutics, Inc.'s net income of -$83.2M. Notably, Merck & Co., Inc.'s price-to-earnings ratio is 13.53x while Cidara Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck & Co., Inc. is 4.03x versus 55.23x for Cidara Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of 33.68% compared to Merck & Co., Inc.'s net margin of -19.69%. Merck & Co., Inc.'s return on equity of 39.63% beat Moderna, Inc.'s return on equity of -30.18%.

Merck & Co., Inc. has a consensus price target of $105.35, signalling upside risk potential of 3.01%. On the other hand Moderna, Inc. has an analysts' consensus of $35.78 which suggests that it could grow by 42.09%. Given that Moderna, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Moderna, Inc. is more attractive than Merck & Co., Inc..

Merck & Co., Inc. has a beta of 0.294, which suggesting that the stock is 70.604% less volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.109, suggesting its more volatile than the S&P 500 by 10.882%.

Merck & Co., Inc. has a quarterly dividend of $0.81 per share corresponding to a yield of 3.17%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merck & Co., Inc. pays 46.32% of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Merck & Co., Inc. quarterly revenues are $17.2B, which are larger than Moderna, Inc. quarterly revenues of $1B. Merck & Co., Inc.'s net income of $5.8B is higher than Moderna, Inc.'s net income of -$200M. Notably, Merck & Co., Inc.'s price-to-earnings ratio is 13.53x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck & Co., Inc. is 4.03x versus 4.37x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of 33.68% compared to Merck & Co., Inc.'s net margin of 38.89%. Merck & Co., Inc.'s return on equity of 39.63% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

Merck & Co., Inc. has a consensus price target of $105.35, signalling upside risk potential of 3.01%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $768.36 which suggests that it could grow by 6.18%. Given that Regeneron Pharmaceuticals, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Regeneron Pharmaceuticals, Inc. is more attractive than Merck & Co., Inc..

Merck & Co., Inc. has a beta of 0.294, which suggesting that the stock is 70.604% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.

Merck & Co., Inc. has a quarterly dividend of $0.81 per share corresponding to a yield of 3.17%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.49% to investors and pays a quarterly dividend of $0.88 per share. Merck & Co., Inc. pays 46.32% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Merck & Co., Inc. quarterly revenues are $17.2B, which are larger than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Merck & Co., Inc.'s net income of $5.8B is higher than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Merck & Co., Inc.'s price-to-earnings ratio is 13.53x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 17.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck & Co., Inc. is 4.03x versus 5.60x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.